BioCentury
ARTICLE | Finance

$40M series A sets up HemoShear to complete evolution from service play to clinical-stage biotech 

February 13, 2021 3:06 AM UTC

After securing $40 million in its first institutional round this week, HemoShear will make the next step in its evolution from service play to drug developer with in-house metabolic disease programs in Phase II testing. 

Suvretta Capital Management led the financing, joined by Janus Henderson Investors, Adage Capital Management and undisclosed private investors...